Zollner Schwetz

Dr. Zollner Schwetz

Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Austria

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
ELEva Leitner
Eva Leitner
GZGernot Zarfel
Gernot Zarfel
JLJosefa Luxner
Josefa Luxner
KHKathrin Herzog
Kathrin Herzog
SPShiva Pekard-Amenitsch
Shiva Pekard-Amenitsch
ZSZollner Schwetz
Zollner Schwetz
We investigated sinks as possible sources of a prolonged Klebsiella pneumonia carbapenemase (KPC)-producing Klebsiella oxytoca outbreak. Seven carbapenem-resistant K. oxytoca isolates were identified in sink drains in 4 patient rooms and in the medication room. Investigations for resistance genes and genetic relatedness of patient and environmental isolates revealed that all the isolates harbored the bla KPC-2 and bla TEM-1 genes and were genetically indistinguishable. We describe here a clonal outbreak caused by KPC-2-producing K. oxytoca , and handwashing sinks were a possible reservoir.

1 April 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
SWS. Wunsch
S. Wunsch
RKR. Krause
R. Krause
TVT. Valentin
T. Valentin
JPJ. Prattes
J. Prattes
OJO. Janata
O. Janata
ZSZollner Schwetz
Zollner Schwetz
Dalbavancin, a lipoglycopeptide with prolonged half-life approved for the treatment of acute bacterial skin and soft tissue infections, can be used for the treatment of infections caused by gram-positive bacteria requiring long term treatment such as endocarditis, prosthetic joint infections (PJI) or osteomyelitis. Clinical data are limited in these settings. To evaluate indications, safety, tolerability and long-term outcomes of dalbavancin-treated patients. Patients and methods Our multicenter, retrospective study includes patients who received dalbavancin in Austria from September 2016 to March 2018. 90-day outcomes and tolerability were determined. A total of 101 patients were included in 3 centers (57% male, median age 65 years). The treated infections were PJI (31%), osteomyelitis (29%), endocarditis (25%) and acute bacterial skin and soft tissue infections (12%). Concomitant use of other antimicrobial substances was common (63%). The mean total cumulative dose of dalbavancin was 3,357mg (±2,283mg). Clinical success rate was 89%. Side effects occurred in 3/101 patients. In this real-life study dalbavancin was primarily used in off-label indications for treatment of PJI, osteomyelitis and endocarditis. Success rate was high (89%), tolerability and safety were excellent in this setting. Dalbavancin may therefore be used in these off-label indications as alternative treatment approach.

22 June 2020 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
CZChristoph Zurl
Christoph Zurl
MWMaximilian Waller
Maximilian Waller
FSFranz Schwameis
Franz Schwameis
TMTina Muhr
Tina Muhr
NBNorbert Bauer
Norbert Bauer
Robert KrauseRobert Krause
Robert Krause
Isavuconazole (ISA) is a triazole antifungal agent recommended for treatment of invasive aspergillosis or mucormycosis. The objective of this study was to evaluate ISA levels in a real world setting in a mixed patient cohort including patients with non-malignant diseases and extracorporeal treatments, and to correlate findings with efficacy and safety outcomes. We investigated 33 ISA treatment courses in 32 adult patients with hematological and other underlying diseases and assessed the clinical response, side effects and ISA trough plasma concentrations. ISA treatment led to complete and partial response in 87% of patients and was well tolerated. The median ISA plasma concentration was 3.05 µg/mL (range 1.38–9.1, IQR 1.93–4.35) in patients without renal replacement therapy (RRT) or extracorporeal membrane oxygenation (ECMO) and significantly lower in patients with RRT including cases with additional ECMO or Cytosorb® adsorber therapy (0.88 µg/mL, range 0.57–2.44, IQR 0.71–1.21). After exclusion of values obtained from four patients with ECMO or Cytosorb® adsorber the median concentration was 0.91 µg/mL (range 0.75–2.44, IQR 0.90–1.36) in the RRT group. In addition to previous recommendations we propose to monitor ISA trough plasma concentrations in certain circumstances including RRT, other extracorporeal treatments and obesity.

23 December 2021 in Toxins
Verified
Journal Article
Open access
PDF file
NSNikolaus Schreiber
Nikolaus Schreiber
GHGerald Hackl
Gerald Hackl
ARAlexander Reisinger
Alexander Reisinger
ZSZollner Schwetz
Zollner Schwetz
KEKathrin Eller
Kathrin Eller
Monika Ehling-SchulzMonika Ehling-Schulz
Monika Ehling-Schulz
Bacillus cereus foodborne intoxications and toxicoinfections are on a rise. Usually, symptoms are self-limiting but occasionally hospitalization is necessary. Severe intoxications with the emetic Bacillus cereus toxin cereulide, which is notably resistant heat and acid during cooking, can cause acute liver failure and encephalopathy. We here present a case series of food poisonings in five immunocompetent adults after ingestion of fried rice balls, which were massively contaminated with Bacillus cereus. The patients developed a broad clinical spectrum, ranging from emesis and diarrhoea to life-threatening acute liver failure and acute tubular necrosis of the kidney in the index patient. In the left-over rice ball, we detected 8 × 106Bacillus cereus colony-forming units/g foodstuff, and cereulide in a concentration of 37 μg/g foodstuff, which is one of the highest cereulide toxin contaminations reported so far from foodborne outbreaks. This report emphasizes the potential biological hazard of contaminated rice meals that are not freshly prepared. It exemplifies the necessity of a multidisciplinary approach in cases of Bacillus cereus associated food poisonings to rapidly establish the diagnosis, to closely monitor critically ill patients, and to provide supportive measures for acute liver failure and—whenever necessary—urgent liver transplantation.

1 December 2015 in International Journal of Medical Microbiology
Verified
Journal Article
Closed access
ELEva Leitner
Eva Leitner
ZSZollner Schwetz
Zollner Schwetz
GZGernot Zarfel
Gernot Zarfel
LMLilian Masoud-Landgraf
Lilian Masoud-Landgraf
MGMichael Gehrer
Michael Gehrer
GFGebhard Feierl
Gebhard Feierl

31 May 2021 in Antibiotics
Verified
Journal Article
Open access
PDF file
LBLuis Buzon-Martin
Luis Buzon-Martin
ZSZollner Schwetz
Zollner Schwetz
STSelma Tobudic
Selma Tobudic
ECEmilia Cercenado
Emilia Cercenado
Jaime Lora-TamayoJaime Lora-Tamayo
Jaime Lora-Tamayo
Dalbavancin (DAL) is a lipoglycopeptide with bactericidal activity against a very wide range of Gram-positive microorganisms. It also has unique pharmacokinetic properties, namely a prolonged half-life (around 181 h), which allows a convenient weekly dosing regimen, and good diffusion in bone tissue. These features have led to off-label use of dalbavancin in the setting of bone and joint infection, including prosthetic joint infections (PJI). In this narrative review, we go over the pharmacokinetic and pharmacodynamic characteristics of DAL, along with published in vitro and in vivo experimental models evaluating its activity against biofilm-embedded bacteria. We also examine published experience of osteoarticular infection with special attention to DAL and PJI.